Tremfya Phase III Maintenance Study Results Presented by J&J for Ulcerative Colitis Treatment

J&J, Johnson & Johnson, Tremfya, guselkumab, Phase III trial, maintenance study, ulcerative colitis, inflammatory bowel disease, treatment, efficacy, safety, remission.

Controversy Surrounds FDA’s Fast-Track Approval of Sarepta’s Duchenne Muscular Dystrophy Gene Therapy

FDA, Sarepta Therapeutics, Duchenne Muscular Dystrophy (DMD), gene therapy, accelerated approval, controversy, clinical trials, efficacy, safety, patient advocacy, regulatory process.

Sanofi Restructures US Commercial Vaccine Group Amid Cost-Saving Campaign

Sanofi, Restructuring, US Commercial Vaccine Group, Cost-Savings Campaign, Streamlined Strategic Sales Structure, Evolving Vaccine Market, Optimization for Efficiency and Effectiveness, Employee Support and Outplacement Assistance